{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:15:20Z","timestamp":1789020920542,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Myasthenia gravis (MG) is an autoimmune disease with acquired neuromuscular junction transmission disorders. In the last two decades, various pathogenesis, application of immunosuppressive agents, and targeted immunotherapy have been significant events. However, extracting the most critical information from complex events is very difficult to guide clinical work. Therefore, we used bibliometrics to summarize and look forward.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Science Citation Index Expanded (SCI-E) from the Web of Science Core Collection (WoSCC) database was identified as a source of material for obtaining MG-related articles. Scimago Graphica, CiteSpace, VOSviewer, and bibliometrix were utilized for bibliometric analysis. Knowledge network graphs were constructed and visualized; countries, institutions, authors, journals, references, and keywords were evaluated. In addition, GraphPad Prism and Microsoft Excel 365 were applied for statistical analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>As of October 25, 2022, 9,970 original MG-related articles were used for the bibliometric analysis; the cumulative number of citations to these articles was 236,987, with an H-index of 201. The United States ranked first in terms of the number of publications (2,877) and H-index (134). Oxford has the highest H-index (67), and Udice French Research University has the highest number of publications (319). The author with the highest average number of citations (66.19), publications (151), and H-index (53) was Vincent A. 28 articles have remained in an explosive period of citations. The final screening yielded predictive keywords related to clinical trials and COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We conducted a bibliometric analysis of 9,970 original MG-related articles published between 1966 and 2022. Ultimately, we found that future MG research hotspots include two major parts: (1) studies directly related to MG disease itself: clinical trials of various targeted biological agents; the relationship between biomarkers and therapeutic decisions, pathogenesis and outcome events, ultimately serving individualized management or precision therapy; (2) studies related to MG and COVID-19: different variants of COVID-19 (e.g., Omicron) on MG adverse outcome events; assessment of the safety of different COVID-19 vaccines for different subtypes of MG.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1132201","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T20:21:27Z","timestamp":1677788487000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Fan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8497","article-title":"Myasthenia gravis","volume":"345","author":"Spillane","year":"2012","journal-title":"Bmj"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: Diagnosis and follow-up of 100 consecutive patients","volume":"244","author":"Beekman","year":"1997","journal-title":"J Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.144438","article-title":"Once myasthenic, always myasthenic? observations on the behavior and prognosis of myasthenia gravis in a cohort of 100 patients","volume":"62","author":"Khadilkar","year":"2014","journal-title":"Neurol India"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30363-0","article-title":"Eculizumab: A treatment option for myasthenia gravis","volume":"16","author":"Gilhus","year":"2017","journal-title":"Lancet Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13503","article-title":"The association of British neurologists' myasthenia gravis guidelines","volume":"1412","author":"Sussman","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1102895108","article-title":"Age dynamics in scientific creativity","volume":"108","author":"Jones","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1023\/a:1024940629314","article-title":"Bursty and hierarchical structure in streams","volume":"7","author":"Kleinberg","year":"2003","journal-title":"Data Min Knowledge Discovery"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.998217","article-title":"Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis","volume":"13","author":"Su","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.2044.493","article-title":"Clinical lecture on cases of myasthenia gravis pseudo-paralytica: Delivered at the national hospital for the paralysed and epileptic","volume":"1","author":"Buzzard","year":"1900","journal-title":"Br Med J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/tomography8030102","article-title":"The h index myth: A form of fanaticism or a simple misconception","volume":"8","author":"Quaia","year":"2022","journal-title":"Tomography"},{"key":"B18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.joi.2007.02.001","article-title":"The h-index: Advantages, limitations and its relation with other bibliometric indicators at the micro level","volume":"1","author":"Costas","year":"2007","journal-title":"J Informetrics"},{"key":"B19","article-title":"Knowledge structure analysis of heat wave based on citespace","volume":"16","year":"2020","journal-title":"Progressus Inquisitiones Mutatione Climatis"},{"key":"B20","volume":"40","year":"2020","journal-title":"Acta Ecologica Sin"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.19029644.v2","article-title":"Citespace demo data","author":"Jie","year":"2022","journal-title":"Figshare"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216408.g002","article-title":"Vosviewer maps of profile descriptions for each dimension","author":"Diaz-Faes","year":"2019","journal-title":"Figshare"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216408.g001","article-title":"Vosviewer map of factor scores and profile descriptions","author":"Diaz-Faes","year":"2019","journal-title":"Figshare"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.joi.2017.08.007","article-title":"Bibliometrix: An r-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetrics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B26","volume-title":"The state of U.S. science and engineering 2020","year":"2020"},{"key":"B27","article-title":"2019 Chinese science and technology paper statistics released: From seeking quantity to focus on quality evaluation indicators change significantly","author":"Zhang","year":"2019"},{"key":"B28","volume-title":"Statistics of national natural science foundation of China funded projects in 2019","year":"2019"},{"key":"B29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40120-021-00292-x","article-title":"Risk factors for generalization in patients with ocular myasthenia gravis: A multicenter retrospective cohort study","volume":"11","author":"Guo","year":"2022","journal-title":"Neurol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15292","article-title":"Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: A propensity score analysis","volume":"29","author":"Ruan","year":"2022","journal-title":"Eur J Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.895007","article-title":"Development and validation of a nomogram for predicting generalization in patients with ocular myasthenia gravis","volume":"13","author":"Ruan","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.753247","article-title":"Antibodies to full-length agrin protein in Chinese patients with myasthenia gravis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (Regain): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during regain and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (Adapt): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001116","article-title":"Igg4-mediated neurologic autoimmunities: Understanding the pathogenicity of Igg4, ineffectiveness of ivig, and long-lasting benefits of anti-b cell therapies","volume":"9","author":"Dalakas","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000009566","article-title":"Covid-19 and neuromuscular disorders","volume":"94","author":"Guidon","year":"2020","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11140-9","article-title":"Vaccines and myasthenia gravis: A comprehensive review and retrospective study of sars-Cov-2 vaccination in a Large cohort of myasthenic patients","volume":"269","author":"Sansone","year":"2022","journal-title":"J Neurol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jns.12482","article-title":"Covid-19 and the peripheral nervous system. a 2-year review from the pandemic to the vaccine era","volume":"27","author":"Taga","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733418","article-title":"To be or not to be vaccinated: That is a question in myasthenia gravis","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: The rinomax randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-092419-031130","article-title":"Age-associated b cells","volume":"38","author":"Cancro","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/imr.12860","article-title":"T Follicular helper cells in germinal center b cell selection and lymphomagenesis","volume":"296","author":"Mintz","year":"2020","journal-title":"Immunol Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"Plasma cells and antibody repertoires in the tumour microenvironment","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0273-0","article-title":"Jak-stat pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.161","article-title":"The Nlrp3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0277-8","article-title":"The il-1 family of cytokines and receptors in rheumatic diseases","volume":"15","author":"Dinarello","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in covid-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"113778","DOI":"10.1016\/j.addr.2021.04.016","article-title":"Prevention of diabetes-associated fibrosis: Strategies in fcrn-targeted nanosystems for oral drug delivery","volume":"175","author":"Azevedo","year":"2021","journal-title":"Adv Drug Delivery Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting fcrn for immunomodulation: Benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting fcrn to generate antibody-based therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: Single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1132201\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T20:21:35Z","timestamp":1677788495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1132201\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2023.1132201"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1132201","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"article-number":"1132201"}}